Vanguard Group Inc. Has $5.97 Billion Holdings in Edwards Lifesciences Corporation $EW

Vanguard Group Inc. decreased its holdings in Edwards Lifesciences Corporation (NYSE:EW) by 0.4% during the 4th quarter, HoldingsChannel.com reports. The firm owned 70,079,435 shares of the medical research company’s stock after selling 283,775 shares during the period. Vanguard Group Inc. owned 0.12% of Edwards Lifesciences worth $5,974,272,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also bought and sold shares of EW. Wellington Management Group LLP raised its position in Edwards Lifesciences by 4.9% during the 3rd quarter. Wellington Management Group LLP now owns 20,804,416 shares of the medical research company’s stock worth $1,617,959,000 after purchasing an additional 977,933 shares during the last quarter. Bank of New York Mellon Corp grew its position in shares of Edwards Lifesciences by 8.1% in the 3rd quarter. Bank of New York Mellon Corp now owns 19,010,227 shares of the medical research company’s stock valued at $1,478,425,000 after buying an additional 1,423,365 shares during the last quarter. Jennison Associates LLC increased its stake in shares of Edwards Lifesciences by 19.6% in the third quarter. Jennison Associates LLC now owns 13,958,774 shares of the medical research company’s stock valued at $1,085,574,000 after buying an additional 2,287,783 shares during the period. Ninety One UK Ltd increased its stake in shares of Edwards Lifesciences by 14.0% in the third quarter. Ninety One UK Ltd now owns 7,908,572 shares of the medical research company’s stock valued at $615,050,000 after buying an additional 969,030 shares during the period. Finally, UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC raised its position in shares of Edwards Lifesciences by 278.3% during the third quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 5,584,646 shares of the medical research company’s stock worth $434,318,000 after acquiring an additional 4,108,270 shares during the last quarter. 79.46% of the stock is currently owned by institutional investors and hedge funds.

Edwards Lifesciences Trading Up 0.1%

NYSE EW opened at $84.20 on Monday. The business has a 50 day simple moving average of $81.71 and a 200 day simple moving average of $82.29. Edwards Lifesciences Corporation has a one year low of $72.30 and a one year high of $87.89. The stock has a market capitalization of $48.55 billion, a P/E ratio of 46.01, a P/E/G ratio of 2.18 and a beta of 0.95. The company has a debt-to-equity ratio of 0.06, a current ratio of 3.72 and a quick ratio of 3.09.

Edwards Lifesciences (NYSE:EW) last issued its quarterly earnings results on Thursday, April 23rd. The medical research company reported $0.78 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.73 by $0.05. The firm had revenue of $1.65 billion for the quarter, compared to analyst estimates of $1.60 billion. Edwards Lifesciences had a return on equity of 14.45% and a net margin of 17.39%.The company’s revenue was up 16.7% compared to the same quarter last year. During the same period in the previous year, the firm earned $0.64 earnings per share. Edwards Lifesciences has set its FY 2026 guidance at 2.950-3.050 EPS and its Q2 2026 guidance at 0.700-0.760 EPS. Research analysts expect that Edwards Lifesciences Corporation will post 2.98 earnings per share for the current year.

Key Headlines Impacting Edwards Lifesciences

Here are the key news stories impacting Edwards Lifesciences this week:

• Positive Sentiment: Q1 beat and raised FY26 outlook — Edwards reported adjusted EPS above consensus and roughly matched/beat revenue, then raised its FY26 EPS and sales guidance (EPS range $2.95–$3.05; sales growth guidance raised). This is the primary driver behind the stock rally. EW’s Q1 Earnings Beat, Revenues Match, ’26 View Up, Stock Climbs
• Positive Sentiment: Strong structural‑heart momentum and margin expansion — Management highlighted accelerating TAVR and TMTT growth, margin improvement and product momentum (including recent approvals), which supports higher longer‑term profitability expectations. Edwards Lifesciences beats quarterly estimates on robust demand for artificial heart valves
• Positive Sentiment: Capital return and buyback activity — Company disclosed a $500M accelerated share‑repurchase during the quarter, which supports EPS leverage and likely contributed to positive investor reaction. Edwards Lifesciences jumps 5.2% as Q1 results top expectations and full-year guidance rises
• Positive Sentiment: Analyst support — Some firms raised price targets/ratings (BTIG raised its target and reiterated buy), reinforcing bullish sentiment after the print. Price target / analyst notes
• Neutral Sentiment: Q2 guidance roughly in line — Q2 EPS guidance of $0.70–$0.76 sits around consensus, so the print is more notable for the FY lift than an outsized Q2 beat. Q1 earnings call highlights
• Neutral Sentiment: Mixed metric reporting from third parties — Some outlets show differing adjusted vs. GAAP EPS or alternate line‑item figures; these reconcileable reporting differences may cause short‑term noise. Q1 financial snapshot (third‑party)
• Negative Sentiment: Substantial insider selling — Public filings and aggregators show multiple insider sales (many executives selling shares) over recent months, which some investors interpret as a negative signal on near‑term insider conviction. Insider trading summary
• Negative Sentiment: Cost pressures — Cost of sales rose noticeably year‑over‑year (reported by some summaries), which could limit margin upside if the trend continues despite current operating margin gains. Cost / margin details

Analysts Set New Price Targets

Several analysts recently commented on EW shares. Evercore reiterated an “outperform” rating and issued a $93.00 target price on shares of Edwards Lifesciences in a report on Friday. UBS Group restated a “neutral” rating and set a $94.00 price target on shares of Edwards Lifesciences in a report on Wednesday, February 4th. Barclays restated an “overweight” rating and issued a $104.00 price target (up from $103.00) on shares of Edwards Lifesciences in a research report on Monday, January 12th. BTIG Research increased their price objective on shares of Edwards Lifesciences from $98.00 to $100.00 and gave the stock a “buy” rating in a research report on Friday. Finally, Wells Fargo & Company lifted their target price on shares of Edwards Lifesciences from $96.00 to $100.00 and gave the stock an “overweight” rating in a research note on Wednesday, February 11th. Three research analysts have rated the stock with a Strong Buy rating, sixteen have issued a Buy rating and nine have issued a Hold rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $95.39.

Insider Activity

In related news, VP Donald E. Bobo, Jr. sold 22,680 shares of the business’s stock in a transaction on Thursday, April 2nd. The shares were sold at an average price of $80.16, for a total transaction of $1,818,028.80. Following the transaction, the vice president owned 21,266 shares in the company, valued at $1,704,682.56. The trade was a 51.61% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, VP Daniel J. Lippis sold 1,019 shares of the stock in a transaction on Monday, April 6th. The stock was sold at an average price of $80.98, for a total transaction of $82,518.62. Following the transaction, the vice president directly owned 33,934 shares in the company, valued at approximately $2,747,975.32. This represents a 2.92% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 86,058 shares of company stock worth $7,118,636 in the last quarter. 0.31% of the stock is owned by corporate insiders.

Edwards Lifesciences Profile

Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.

In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.